<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697719</url>
  </required_header>
  <id_info>
    <org_study_id>20-01884</org_study_id>
    <nct_id>NCT04697719</nct_id>
  </id_info>
  <brief_title>Body Weight, Aspirin Dose and Pro-resolving Mediators</brief_title>
  <official_title>DISCOVER: A Single-site Double-blind Placebo-controlled Randomized Mechanistic Crossover Trial to Assess the Influence of boDy weIght on aSpirin-triggered speCialized prO-resolVing mEdiatoRs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study employs a placebo-controlled randomized cross-over design to investigate the&#xD;
      impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators&#xD;
      in blood and neutrophils.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a two-phase crossover design with run-in and wash out periods prior to each phase.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum 15R-LXA4</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum 15R-LXA4</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum and neutrophil supernatant lipid mediators</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum and neutrophil supernatant lipid mediators</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet-monocyte aggregates</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet-monocyte aggregates</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet-neutrophil aggregates</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet-neutrophil aggregates</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet surface expression of CD62P</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet surface expression of CD62P</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leukocyte expression of ALX/FPR2</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leukocyte expression of ALX/FPR2</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leukocyte expression of GPR32</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leukocyte expression of GPR32</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leukocyte expression of ERV1/ChemR23</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leukocyte expression of ERV1/ChemR23</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leukocyte expression of BLT1</measure>
    <time_frame>Week 3, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leukocyte expression of BLT1</measure>
    <time_frame>Week 9, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Body Weight</condition>
  <arm_group>
    <arm_group_label>Aspirin 81mg, Then Aspirin 325mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 3 week placebo run-in period, participants first receive Aspirin 81mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 325mg capsule daily for another 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 325mg, Then Aspirin 81mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 3 week placebo run-in period, participants first receive Aspirin 325mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 81mg capsule daily for another 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81mg</intervention_name>
    <description>81mg oral capsule</description>
    <arm_group_label>Aspirin 325mg, Then Aspirin 81mg</arm_group_label>
    <arm_group_label>Aspirin 81mg, Then Aspirin 325mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 325mg</intervention_name>
    <description>325mg oral capsule</description>
    <arm_group_label>Aspirin 325mg, Then Aspirin 81mg</arm_group_label>
    <arm_group_label>Aspirin 81mg, Then Aspirin 325mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Age between 40 and 70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anti-platelet medication use in the past 7 days&#xD;
&#xD;
          2. Aspirin intolerance or allergy&#xD;
&#xD;
          3. Known bleeding or clotting disorder&#xD;
&#xD;
          4. Chronic inflammatory or connective tissue disease&#xD;
&#xD;
          5. Immunological deficiency&#xD;
&#xD;
          6. Diabetes mellitus&#xD;
&#xD;
          7. Prior gastric or bariatric surgery&#xD;
&#xD;
          8. Active smoking&#xD;
&#xD;
          9. Platelet count &lt;100,000&#xD;
&#xD;
         10. Use of omega-3 fatty acid supplementation&#xD;
&#xD;
         11. Use of drugs or supplements known to inhibit COX-1/COX-2/lipoxygenases&#xD;
&#xD;
         12. Corticosteroid use&#xD;
&#xD;
         13. Recent initiation or change in dose of statin therapy&#xD;
&#xD;
         14. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Heffron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sean Heffron, MD</last_name>
    <phone>646-501-2735</phone>
    <email>Sean.Heffron@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalie McGowan, BS</last_name>
    <phone>646-819-2034</phone>
    <email>Natalie.Mcgowan@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Heffron, MD</last_name>
      <email>Sean.Heffron@nyulangone.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to sean.heffron@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

